Phase I-II trial of TLK286 (telcyta), carboplatin (C), and paclitaxel (P) as first-line treatment for advanced non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Sequist, L
Fidias, P
Temel, J
Kennedy, E
Ostler, P
Rabin, M
Huberman, M
Keck, J
Brown, G
Lynch, T
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[4] Telik Inc, Palo Alto, CA USA
来源：
LUNG CANCER | 2005年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S269 / S269
页数：1
相关论文
共 50 条
  • [21] A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC)
    Cohen, Roger B.
    Langer, Corey J.
    Simon, George Rajan
    Eisenberg, Peter David
    Hainsworth, John Daniel
    Madajewicz, Stefan
    Cosgriff, Thomas Michael
    Pierce, Kristen
    Xu, Huiping
    Liau, Katherine
    Healey, Diane
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 60 (01) : 81 - 89
  • [22] Phase II study of meloxicam with carboplatin plus docetaxel in first-line treatment of patients with advanced non-small cell lung cancer (NSCLC)
    Ishida, T.
    Kanazawa, K.
    Oizumi, H.
    Yokouchi, H.
    Yamazaki, K.
    Akie, K.
    Sukoh, N.
    Harada, M.
    Munakata, M.
    Isobe, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [23] A phase II trial of weekly paclitaxel and carboplatin for elderly patients with advanced non-small cell lung cancer (NSCLC).
    Usui, K
    Inoue, A
    Ishimoto, O
    Tanaka, M
    Koinumaru, S
    Matsubara, N
    Kanbe, M
    Gomi, K
    Saijo, Y
    Nukiwa, T
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 682S - 682S
  • [24] TLK-286 enters phase II trial for non-small cell lung cancer
    不详
    DRUG NEWS & PERSPECTIVES, 2001, 14 (05) : 296 - 297
  • [25] A phase I trial of paclitaxel, carboplatin, and gemcitabine in advanced non-small cell lung cancer
    Kelly, K
    Prindiville, S
    Bunn, PA
    SEMINARS IN ONCOLOGY, 1999, 26 (01) : 74 - 74
  • [26] Analysis of Outcomes in Diabetic Patients in a Phase 3 Trial of Nab-Paclitaxel (nab-P) Plus Carboplatin (C) in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
    Hirsh, V.
    Owen, S. P.
    Ko, A.
    Renschler, M.
    Socinski, M. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S21 - S21
  • [27] BIWEEKLY CARBOPLATIN AND PACLITAXEL AS FIRST-LINE THERAPY FOR ELDERLY ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS (PHASE II STUDY)
    Kota, I.
    Soejima, K.
    Naoki, K.
    Yasuda, H.
    Terai, H.
    Daisuke, A.
    Ohgino, K.
    Yoda, S.
    Ikemura, S.
    Betsuyaku, T.
    ANNALS OF ONCOLOGY, 2012, 23 : 422 - 422
  • [28] A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC)
    Hidehito Horinouchi
    Noboru Yamamoto
    Hiroshi Nokihara
    Takeshi Horai
    Makoto Nishio
    Fumiyoshi Ohyanagi
    Atsushi Horiike
    Kazuhiko Nakagawa
    Masaaki Terashima
    Takafumi Okabe
    Hiroyasu Kaneda
    Mark D. McKee
    Dawn M. Carlson
    Hao Xiong
    Tomohide Tamura
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 37 - 43
  • [29] A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC)
    Horinouchi, Hidehito
    Yamamoto, Noboru
    Nokihara, Hiroshi
    Horai, Takeshi
    Nishio, Makoto
    Ohyanagi, Fumiyoshi
    Horiike, Atsushi
    Nakagawa, Kazuhiko
    Terashima, Masaaki
    Okabe, Takafumi
    Kaneda, Hiroyasu
    McKee, Mark D.
    Carlson, Dawn M.
    Xiong, Hao
    Tamura, Tomohide
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (01) : 37 - 43
  • [30] Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 as first line treatment of advanced non-small cell lung cancer (NSCLC)
    Hirsh, V.
    Boyer, M.
    Rosell, R.
    Benner, R. J.
    Readett, D.
    Schiller, J. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345